RPS-BLAST 2.2.26 [Sep-21-2011]

Database: CDD.v3.10 
           44,354 sequences; 10,937,602 total letters

Searching..................................................done

Query= psy11633
         (127 letters)



>gnl|CDD|199822 cd10497, MH2_SMAD_1_5_9, C-terminal Mad Homology 2 (MH2) domain in
           SMAD1, SMAD5 and SMAD9.  The MH2 domain is located at
           the C-terminus of the SMAD (small mothers against
           decapentaplegic) family of proteins, which are signal
           transducers and transcriptional modulators that mediate
           multiple signaling pathways. The MH2 domain is
           responsible for type I receptor interaction,
           phosphorylation-triggered homo- and
           hetero-oligomerization, and transactivation. It is
           negatively regulated by the N-terminal MH1 domain, which
           prevents it from forming a complex with SMAD4. SMAD1,
           SMAD5 and SMAD9 (also known as SMAD8), are receptor
           regulated SMADs (R-SMADs). SMAD1 plays an essential role
           in bone development and postnatal bone formation through
           activation by bone morphogenetic protein (BMP) type 1
           receptor kinase. SMAD5 is involved in BMP signal
           modulation and may also play a role in the pathway
           involving inhibition of hematopoietic progenitor cells
           by TGF-beta. SMAD9 mediates the differentiation of
           mesenchymal stem cells (MSCs) into tendon-like cells by
           inhibiting the osteogenic pathway.
          Length = 201

 Score =  128 bits (323), Expect = 1e-38
 Identities = 51/53 (96%), Positives = 51/53 (96%)

Query: 75  RMSFVKGWGAEYHRQDVTSTPCWIEIHLHGPLQWLDKVLIQMGSPHQPISSVS 127
           RMSFVKGWGAEYHRQDVTSTPCWIEIHLHGPLQWLDKVL QMGSPH PISSVS
Sbjct: 149 RMSFVKGWGAEYHRQDVTSTPCWIEIHLHGPLQWLDKVLTQMGSPHNPISSVS 201


>gnl|CDD|199820 cd10495, MH2_R-SMAD, C-terminal Mad Homology 2 (MH2) domain in
           receptor regulated SMADs.  The MH2 domain is located at
           the C-terminus of the SMAD (small mothers against
           decapentaplegic) family of proteins, which are signal
           transducers and transcriptional modulators that mediate
           multiple signaling pathways. The MH2 domain is
           responsible for type I receptor interaction,
           phosphorylation-triggered homo- and
           hetero-oligomerization, and transactivation. It is
           negatively regulated by the N-terminal MH1 domain.
           Receptor regulated SMADs (R-SMADs) include SMAD1, SMAD2,
           SMAD3, SMAD5 and SMAD9. SMAD1 plays an essential role in
           bone development and postnatal bone formation through
           activation by bone morphogenetic protein (BMP) type 1
           receptor kinase. SMAD2 regulates multiple cellular
           processes, such as cell proliferation, apoptosis and
           differentiation, while SMAD3 modulates signals of
           activin and TGF-beta. SMAD5 is involved in BMP signal
           modulation, possibly playing a role in the pathway
           involving inhibition of hematopoietic progenitor cells
           by TGF-beta. SMAD9 (also known as SMAD8) can mediate the
           differentiation of mesenchymal stem cells into
           tendon-like cells by inhibiting the osteogenic pathway.
          Length = 182

 Score =  102 bits (256), Expect = 1e-28
 Identities = 38/39 (97%), Positives = 39/39 (100%)

Query: 75  RMSFVKGWGAEYHRQDVTSTPCWIEIHLHGPLQWLDKVL 113
           R+SFVKGWGAEYHRQDVTSTPCWIEIHLHGPLQWLDKVL
Sbjct: 143 RISFVKGWGAEYHRQDVTSTPCWIEIHLHGPLQWLDKVL 181


>gnl|CDD|199826 cd10985, MH2_SMAD_2_3, C-terminal Mad Homology 2 (MH2) domain in
           SMAD2 and SMAD3.  The MH2 domain is located at the
           C-terminus of the SMAD (small mothers against
           decapentaplegic) family of proteins, which are signal
           transducers and transcriptional modulators that mediate
           multiple signaling pathways. The MH2 domain is
           responsible for type I receptor interaction,
           phosphorylation-triggered homo- and
           hetero-oligomerization, and transactivation. It is
           negatively regulated by the N-terminal MH1 domain. SMAD2
           and SMAD3 are receptor regulated SMADs (R-SMADs). SMAD2
           regulates multiple cellular processes, such as cell
           proliferation, apoptosis and differentiation, while
           SMAD3 modulates signals of activin and TGF-beta.
          Length = 191

 Score = 93.5 bits (232), Expect = 5e-25
 Identities = 36/42 (85%), Positives = 39/42 (92%)

Query: 75  RMSFVKGWGAEYHRQDVTSTPCWIEIHLHGPLQWLDKVLIQM 116
           RMSFVKGWGAEY RQ VTSTPCWIE+HL+GPLQWLD+VL QM
Sbjct: 150 RMSFVKGWGAEYRRQTVTSTPCWIELHLNGPLQWLDRVLTQM 191


>gnl|CDD|199823 cd10498, MH2_SMAD_4, C-terminal Mad Homology 2 (MH2) domain in
           SMAD4.  The MH2 domain is located at the C-terminus of
           the SMAD (small mothers against decapentaplegic) family
           of proteins, which are signal transducers and
           transcriptional modulators that mediate multiple
           signaling pathways. The MH2 domain is responsible for
           type I receptor interaction, phosphorylation-triggered
           homo- and hetero-oligomerization, and transactivation.
           It is negatively regulated by the N-terminal MH1 domain.
           SMAD4, which belongs to the Dwarfin family of proteins,
           is involved in many cell functions such as
           differentiation, apoptosis, gastrulation, embryonic
           development and the cell cycle. SMAD4 binds receptor
           regulated SMADs (R-SMADs) such as SMAD1 or SMAD2, and
           forms an oligomeric complex that binds to DNA and serves
           as a transcription factor. SMAD4 is often mutated in
           several cancers, such as multiploid colorectal cancer,
           cervical cancer and pancreatic carcinoma, as well as in
           juvenile polyposis syndrome.
          Length = 222

 Score = 77.1 bits (190), Expect = 2e-18
 Identities = 29/41 (70%), Positives = 32/41 (78%)

Query: 73  ISRMSFVKGWGAEYHRQDVTSTPCWIEIHLHGPLQWLDKVL 113
           I RMSFVKGWG +Y RQ +  TPCWIEIHLH  LQ LD+VL
Sbjct: 181 ILRMSFVKGWGPDYPRQSIKETPCWIEIHLHRALQLLDEVL 221


>gnl|CDD|217398 pfam03166, MH2, MH2 domain.  This is the MH2 (MAD homology 2)
           domain found at the carboxy terminus of MAD related
           proteins such as Smads. This domain is separated from
           the MH1 domain by a non-conserved linker region. The MH2
           domain mediates interaction with a wide variety of
           proteins and provides specificity and selectivity to
           Smad function and also is critical for mediating
           interactions in Smad oligomers. Unlike MH1, MH2 does not
           bind DNA. The well-studied MH2 domain of Smad4 is
           composed of five alpha helices and three loops enclosing
           a beta sandwich. Smads are involved in the propagation
           of TGF-beta signals by direct association with the
           TGF-beta receptor kinase which phosphorylates the last
           two Ser of a conserved 'SSXS' motif located at the
           C-terminus of MH2.
          Length = 179

 Score = 74.7 bits (184), Expect = 5e-18
 Identities = 23/31 (74%), Positives = 28/31 (90%)

Query: 75  RMSFVKGWGAEYHRQDVTSTPCWIEIHLHGP 105
           R+SFVKGWG +Y RQD+TSTPCWIE+HL+ P
Sbjct: 149 RISFVKGWGEDYPRQDITSTPCWIEVHLNRP 179


>gnl|CDD|199819 cd00050, MH2, C-terminal Mad Homology 2 (MH2) domain.  The MH2
           domain is found in the SMAD (small mothers against
           decapentaplegic) family of proteins and is responsible
           for type I receptor interactions,
           phosphorylation-triggered homo- and
           hetero-oligomerization, and transactivation. It is
           negatively regulated by the N-terminal MH1 domain which
           prevents it from forming a complex with SMAD4. The MH2
           domain is multifunctional and provides SMADs with their
           specificity and selectivity, as well as transcriptional
           activity. Several transcriptional co-activators and
           repressors have also been reported to regulate SMAD
           signaling by interacting with the MH2 domain. Mutations
           in the MH2 domains of SMAD2 and especially SMAD4 have
           been detected  in colorectal and other human cancers.
          Length = 170

 Score = 73.4 bits (180), Expect = 1e-17
 Identities = 27/29 (93%), Positives = 28/29 (96%)

Query: 75  RMSFVKGWGAEYHRQDVTSTPCWIEIHLH 103
           RMSFVKGWG EYHRQD+TSTPCWIEIHLH
Sbjct: 142 RMSFVKGWGPEYHRQDITSTPCWIEIHLH 170


>gnl|CDD|197770 smart00524, DWB, Domain B in dwarfin family proteins. 
          Length = 171

 Score = 70.8 bits (174), Expect = 2e-16
 Identities = 21/31 (67%), Positives = 26/31 (83%)

Query: 73  ISRMSFVKGWGAEYHRQDVTSTPCWIEIHLH 103
             R+SFVKGWG +Y RQ +TSTPCWIE+HL+
Sbjct: 141 TIRISFVKGWGPDYSRQTITSTPCWIEVHLN 171


>gnl|CDD|199821 cd10496, MH2_I-SMAD, C-terminal Mad Homology 2 (MH2) domain in
           Inhibitory SMADs.  The MH2 domain is located at the
           C-terminus of the SMAD (small mothers against
           decapentaplegic) family of proteins, which are signal
           transducers and transcriptional modulators that mediate
           multiple signaling pathways. The MH2 domain is
           responsible for type I receptor interaction,
           phosphorylation-triggered homo- and
           hetero-oligomerization, and transactivation. It is
           negatively regulated by the N-terminal MH1 domain, which
           prevents it from forming a complex with SMAD4. SMAD6 and
           SMAD7 are inhibitory SMADs (I-SMADs) that function as
           negative regulators of signaling mediated by the
           TGF-beta superfamily. SMAD6 specifically inhibits bone
           morphogenetic protein (BMP) type I receptor mediated
           signaling, while SMAD7 enhances muscle differentiation
           and is often associated with cancer, tissue fibrosis and
           inflammatory diseases.
          Length = 165

 Score = 56.2 bits (136), Expect = 5e-11
 Identities = 19/28 (67%), Positives = 22/28 (78%)

Query: 75  RMSFVKGWGAEYHRQDVTSTPCWIEIHL 102
           R+SFVKGWG  Y RQ +TS PCW+EI L
Sbjct: 137 RISFVKGWGPNYSRQFITSCPCWLEILL 164


>gnl|CDD|199824 cd10499, MH2_SMAD_6, C-terminal Mad Homology 2 (MH2) domain in
           SMAD6.  The MH2 domain is located at the C-terminus of
           the SMAD (small mothers against decapentaplegic) family
           of proteins, which are signal transducers and
           transcriptional modulators that mediate multiple
           signaling pathways. The MH2 domain is responsible for
           type I receptor interaction, phosphorylation-triggered
           homo- and hetero-oligomerization, and transactivation.
           It is negatively regulated by the N-terminal MH1 domain,
           which prevents it from forming a complex with SMAD4.
           SMAD6, an inhibitory or antagonistic SMAD (I-SMAD), acts
           as a negative regulator of signaling mediated by the
           TGF-beta superfamily of ligands, by competing with SMAD4
           and preventing the transcription of SMAD4's gene
           products. SMAD6 specifically inhibits bone morphogenetic
           protein (BMP) type I receptor mediated signaling. SMAD6
           and SMAD7 act as critical mediators for effective
           TGF-beta I-mediated suppression of
           Interleukin-1/Toll-like receptor (IL-1R/TLR) signaling
           through simultaneous binding to Pellino-1, an adaptor
           protein of interleukin-1 receptor associated kinase 1
           (IRAK1), via their MH2 domains.
          Length = 174

 Score = 47.9 bits (114), Expect = 8e-08
 Identities = 18/28 (64%), Positives = 21/28 (75%)

Query: 75  RMSFVKGWGAEYHRQDVTSTPCWIEIHL 102
           R+SF KGWG  Y RQ +TS PCW+EI L
Sbjct: 145 RISFAKGWGPCYSRQFITSCPCWLEILL 172


>gnl|CDD|199825 cd10500, MH2_SMAD_7, C-terminal Mad Homology 2 (MH2) domain in
           SMAD7.  The MH2 domain is located at the C-terminus of
           the SMAD (small mothers against decapentaplegic) family
           of proteins, which are signal transducers and
           transcriptional modulators that mediate multiple
           signaling pathways. The MH2 domain is responsible for
           type I receptor interaction, phosphorylation-triggered
           homo- and hetero-oligomerization, and transactivation.
           It is negatively regulated by the N-terminal MH1 domain,
           which prevents it from forming a complex with SMAD4.
           SMAD7, an inhibitory or antagonistic SMAD (I-SMAD), acts
           as a negative regulator of signaling mediated by the
           TGF-beta superfamily of ligands, by blocking TGF-beta
           type 1 and activin association with the receptor as well
           as access to SMAD2. SMAD7 enhances muscle
           differentiation, playing pivotal roles in embryonic
           development and adult homoeostasis. SMAD7 and SMAD6 act
           as critical mediators for effective TGF-beta I-mediated
           suppression of Interleukin-1/Toll-like receptor
           (IL-1R/TLR) signaling through simultaneous binding to
           Pellino-1, an adaptor protein of interleukin-1 receptor
           associated kinase 1(IRAK1), via their MH2 domains.
           Altered expression of SMAD7 is often associated with
           cancer, tissue fibrosis and inflammatory diseases.
          Length = 171

 Score = 40.8 bits (95), Expect = 4e-05
 Identities = 15/26 (57%), Positives = 21/26 (80%)

Query: 75  RMSFVKGWGAEYHRQDVTSTPCWIEI 100
           ++SFVKGWG  Y RQ ++S PCW+E+
Sbjct: 143 QISFVKGWGQCYTRQFISSCPCWLEV 168


>gnl|CDD|221834 pfam12891, Glyco_hydro_44, Glycoside hydrolase family 44.  This is
           a family of bacterial glycoside hydrolases formerly
           known as cellulase family J, and now known as Cel44A. It
           is one of the major enzymatic components of the
           cellulosome of Clostridium thermocellum strain F1 and of
           many other Firmicutes.
          Length = 236

 Score = 29.3 bits (66), Expect = 0.39
 Identities = 15/36 (41%), Positives = 18/36 (50%), Gaps = 3/36 (8%)

Query: 81  GWGAEYHRQDVTSTPCWIEIHLHGPLQWLDKVLIQM 116
           GW A ++ QD    P W +   HG   WLD  L QM
Sbjct: 180 GWCAYFNSQD---APDWSDRKAHGNYPWLDYYLDQM 212


>gnl|CDD|185337 PRK15440, PRK15440, L-rhamnonate dehydratase; Provisional.
          Length = 394

 Score = 28.2 bits (63), Expect = 1.1
 Identities = 13/32 (40%), Positives = 17/32 (53%), Gaps = 3/32 (9%)

Query: 75  RMSFVKGWGAEYHRQDVTSTPCWIEIHLHGPL 106
           R  FV G GA+YH Q       WI+ H+  P+
Sbjct: 10  RAWFVGGGGADYHDQGANH---WIDDHIATPM 38


>gnl|CDD|184188 PRK13626, PRK13626, transcriptional regulator SgrR; Provisional.
          Length = 552

 Score = 27.7 bits (62), Expect = 2.0
 Identities = 14/38 (36%), Positives = 19/38 (50%), Gaps = 4/38 (10%)

Query: 87  HRQDVTS-TPCWIEIHLHGPLQWLDKVLIQMGSPHQPI 123
           H   + S TP  ++IHL  P +WL  +L   GS    I
Sbjct: 216 HIAKIVSPTPWTLDIHLSQPDRWLPWLL---GSVPAMI 250


>gnl|CDD|130849 TIGR01789, lycopene_cycl, lycopene cyclase.  This model represents
           a family of bacterial lycopene cyclases catalyzing the
           transformation of lycopene to carotene. These enzymes
           are found in a limited spectrum of alpha and gamma
           proteobacteria as well as Flavobacterium.
          Length = 370

 Score = 26.0 bits (57), Expect = 6.0
 Identities = 16/60 (26%), Positives = 22/60 (36%), Gaps = 3/60 (5%)

Query: 69  YFVLISRMSFVKGWGAEYHR--QDVTSTP-CWIEIHLHGPLQWLDKVLIQMGSPHQPISS 125
           Y+ L++RM F      +  R  Q         IE          DK+ +  G P  PI S
Sbjct: 309 YYRLLNRMLFFAAKPEKRVRVFQRFYGLREGLIERFYAARSNTFDKLRVLWGKPPVPIHS 368


>gnl|CDD|233208 TIGR00956, 3a01205, Pleiotropic Drug Resistance (PDR) Family protein.
             [Transport and binding proteins, Other].
          Length = 1394

 Score = 26.2 bits (58), Expect = 7.0
 Identities = 18/78 (23%), Positives = 28/78 (35%), Gaps = 22/78 (28%)

Query: 1    MKYLVIIPLSSSYVQLFISLI-------QPSNIFQQLSF-FTQRPIFCIRNKCNRTEIPF 52
            M  ++  PL   Y+  F++         +PS  F  L+F   Q  I          EIP+
Sbjct: 1135 MATVLFNPLIQQYLPPFVAQRDLYEVRERPSRTFSWLAFIAAQ--ITV--------EIPY 1184

Query: 53   AVKVPRQFSLSVIILWYF 70
             +     F       WY+
Sbjct: 1185 NLVAGTIFFFI----WYY 1198


>gnl|CDD|178745 PLN03206, PLN03206, phosphoribosylformylglycinamidine synthase;
           Provisional.
          Length = 1307

 Score = 25.9 bits (57), Expect = 7.7
 Identities = 8/15 (53%), Positives = 11/15 (73%)

Query: 76  MSFVKGWGAEYHRQD 90
           +S ++ WGAEY  QD
Sbjct: 532 LSVLEIWGAEYQEQD 546


  Database: CDD.v3.10
    Posted date:  Mar 20, 2013  7:55 AM
  Number of letters in database: 10,937,602
  Number of sequences in database:  44,354
  
Lambda     K      H
   0.329    0.140    0.456 

Gapped
Lambda     K      H
   0.267   0.0730    0.140 


Matrix: BLOSUM62
Gap Penalties: Existence: 11, Extension: 1
Number of Sequences: 44354
Number of Hits to DB: 6,288,966
Number of extensions: 528317
Number of successful extensions: 552
Number of sequences better than 10.0: 1
Number of HSP's gapped: 552
Number of HSP's successfully gapped: 24
Length of query: 127
Length of database: 10,937,602
Length adjustment: 85
Effective length of query: 42
Effective length of database: 7,167,512
Effective search space: 301035504
Effective search space used: 301035504
Neighboring words threshold: 11
Window for multiple hits: 40
X1: 15 ( 7.1 bits)
X2: 38 (14.6 bits)
X3: 64 (24.7 bits)
S1: 40 (21.8 bits)
S2: 53 (24.2 bits)